What does a lung-to-head ratio (LHR) of 1.93 indicate about fetal prognosis and recommended management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

LHR 1.93 in Congenital Diaphragmatic Hernia: Favorable Prognosis

An LHR of 1.93 indicates a favorable prognosis with high likelihood of survival in isolated left-sided congenital diaphragmatic hernia (CDH), and this fetus should be managed with expectant care, serial monitoring, and planned delivery at a tertiary center with ECMO capability.

Prognostic Interpretation

An LHR of 1.93 falls well above the critical thresholds that define severe CDH:

  • The cutoff of LHR <1.0 predicts 100% mortality**, while **LHR >1.4 predicts 100% survival in isolated left-sided CDH 1
  • Your value of 1.93 substantially exceeds the 1.4 threshold, placing this fetus in the favorable outcome category
  • Studies demonstrate that LHR is a reliable predictor independent of gestational age at measurement 1

The most recent multicenter data from 2025 establishes that an observed/expected (O/E) LHR of approximately 28-33% represents the threshold for severe disease requiring consideration of fetal intervention 2. An absolute LHR of 1.93 typically corresponds to an O/E LHR well above 40-50%, again indicating favorable prognosis.

Survival Expectations

With an LHR of 1.93, you can counsel families regarding:

  • High probability of survival to hospital discharge (likely >90% based on the threshold data)
  • Lower likelihood of requiring ECMO support 1, 3
  • Reduced risk of severe pulmonary hypertension at one month, though LHR does not predict long-term pulmonary hypertension beyond 3 months 4

Recommended Management Algorithm

Prenatal Surveillance

  • Serial fetal echocardiography every 2-4 weeks until 32 weeks, then every 1-2 weeks to monitor for high-risk features that can manifest later in gestation 5
  • Monitor specifically for: development of hydrops, cardiac dysfunction, liver herniation, polyhydramnios, and fetal growth restriction
  • Consider fetal MRI for total lung volume assessment if available, though with LHR 1.93 this is not essential for prognostication 6

Delivery Planning

Planned delivery must occur at a tertiary/quaternary center with:

  • Pediatric cardiac surgery capability
  • ECMO service availability
  • Neonatal intensive care expertise
  • Immediate access to mechanical ventilation and pulmonary vasodilators 5

This is a Class I recommendation even for favorable LHR values, as acute cardiovascular compromise can occur with the transition from fetal to neonatal circulation when the low-resistance placental circulation is discontinued 5.

Timing of Delivery

  • Aim for delivery at ≥37-38 weeks if no complications develop
  • If preterm delivery anticipated before 34 weeks, administer maternal corticosteroids for fetal lung maturation 5
  • Consider MgSO₄ for neuroprotection if delivery planned before 32 weeks 7

Important Caveats

LHR alone is insufficient - you must also assess:

  • Liver position: Intrathoracic liver herniation worsens prognosis even with favorable LHR 6
  • Cardiac function: Ventricular dysfunction, significant tricuspid regurgitation, or circular shunt physiology dramatically alter outcomes 5
  • Associated anomalies: Ensure truly isolated CDH, as chromosomal abnormalities or other structural defects change counseling entirely

LHR has limitations:

  • Does not predict long-term pulmonary hypertension beyond the neonatal period 4
  • Does not reliably predict chronic lung disease in survivors 8
  • Some studies question its overall utility, particularly when applied inconsistently across centers 9

However, the weight of evidence supports that LHR >1.4, and especially >1.9, reliably predicts survival in isolated left-sided CDH 1, 3.

What NOT to Do

  • Do not offer fetal intervention (such as fetoscopic tracheal occlusion) - this LHR is far above thresholds where fetal surgery would be considered (typically O/E LHR <25-30%) 2
  • Do not deliver at a community hospital - even favorable LHR cases require tertiary center delivery due to unpredictable postnatal transition 5
  • Do not assume normal long-term pulmonary outcomes - even survivors with favorable LHR may develop chronic respiratory issues requiring ongoing follow-up 8

References

Research

The lung-to-head ratio and fetoscopic temporary tracheal occlusion: prediction of survival in severe left congenital diaphragmatic hernia.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2003

Research

Observed-to-expected lung-area-to-head-circumference ratio on ultrasound examination vs total fetal lung volume on magnetic resonance imaging in prediction of survival in fetuses with left-sided diaphragmatic hernia.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2024

Research

How useful is the lung-to-head ratio in predicting outcome in the fetus with congenital diaphragmatic hernia? A systematic review and meta-analysis.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.